RBC Capital Maintains Outperform on Biogen, Raises Price Target to $292
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Biogen (NASDAQ:BIIB) and raises the price target from $282 to $292.
August 02, 2024 | 7:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Biogen and raises the price target from $282 to $292.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Biogen's stock price in the short term. Investors often react favorably to such updates, especially when the price target is increased.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100